This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vgontzas, A. N. Articles by Chrousos, G. P. Search for Related Content PubMed PubMed Citation Articles by Vgontzas, A. N. Articles by Chrousos, G. P.

Elevation of Plasma Cytokines in Disorders of Excessive Daytime Sleepiness: Role of Sleep Disturbance and Obesity

Sleep Research and Treatment Center, Department of Psychiatry, Pennsylvania State University (A.N.V., E.O.B., A.K., K.T.), Hershey, Pennsylvania 17033; the Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health (D.A.P., G.P.C.), Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Alexandros N. Vgontzas, M.D., Sleep Research and Treatment Center, Department of Psychiatry, Pennsylvania State University, 500 University Drive, Hershey, Pennsylvania 17033.

	Abstract

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Excessive daytime sleepiness (EDS) and fatigue are frequent symptoms in the general population and the chief complaint of the majority of patients at Sleep Disorders Centers. There is evidence that the inflammatory cytokines tumor necrosis factor- (TNF), interleukin-1ß (IL-1ß), and IL-6 are involved in physiological sleep regulation and that their administration to humans is associated with sleepiness and fatigue. To explore whether plasma levels of TNF, IL-1ß, and IL-6 are elevated in patients with EDS, we measured morning plasma levels of TNF, IL-1ß, and IL-6 in 12 sleep apneics, 11 narcoleptics, 8 idiopathic hypersomniacs, and 10 normal controls. TNF was significantly elevated in sleep apneics and narcoleptics compared to that in normal controls (P < 0.001 and P = 0.001, respectively). Plasma IL-1ß concentrations were not different between sleep disorder patients and controls, whereas IL-6 was markedly and significantly elevated in sleep apneics compared to that in normal controls (P = 0.028). The primary factor influencing TNF values was the degree of nocturnal sleep disturbance, whereas the primary determinant for IL-6 levels was the body mass index. Our findings suggest that TNF and IL-6 might play a significant role in mediating sleepiness and fatigue in disorders of EDS in humans.

	Introduction

Top Abstract Introduction Subjects and Methods Results Discussion References

 
EXCESSIVE DAYTIME sleepiness (EDS) occurs in about 5% of the general population and is the chief complaint of the majority of patients evaluated at Sleep Disorders Centers (1, 2). Sleep apnea, narcolepsy, and idiopathic hypersomnia are the three most common sleep disorders associated with EDS. No information exists with regard to potential circulating endogenous factors whose alterations could lead to pathological sleepiness in any of these disorders.

The inflammatory cytokines, tumor necrosis factor- (TNF) and interleukin-1 (IL-1) appear to be involved in the regulation of sleep in animals and humans, whereas the exogenous administration of IL-1ß to patients has been associated with somnolence and/or increased sleep (3, 4, 5). IL-6 was reported to be pyrogenic, but not somnogenic, in rabbits (6). However, in a recent study on sleeping sickness (African trypanosomiasis), plasma concentrations of IL-6 were found to be significantly elevated during the course of the illness (7). Also, exogenous administration of IL-6 in patients with cancer (8) or increased production of endogenous IL-6 (9) were associated with increased sleepiness and fatigue, suggesting that IL-6 may also be related to sleep and sleepiness in man.

In this study, we explored whether circulating TNF, IL-1ß, and IL-6 play a potential pathogenetic role in the EDS associated with sleep apnea, narcolepsy, and idiopathic hypersomnia.

	Subjects and Methods

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Subjects

The study population and their clinical profiles are summarized in Table 1. Twelve patients with obstructive sleep apnea, 11 with narcolepsy, 8 with idiopathic hypersomnia, and 10 normal controls were evaluated.

Narcoleptics were defined as those that present with EDS and cataplexy or a sleep-onset rapid eye movement (REM) period during at least one of the morning naps. A sleep-onset REM period was determined as the occurrence of REM sleep within the first 10 min after sleep onset. Finally, patients that presented with EDS and did not meet the criteria for the diagnosis of any other daytime sleepiness disorder (including sleep apnea, narcolepsy, hypersomnia due to a mental disorder, severe snoring, and sleep deprivation) were diagnosed with idiopathic hypersomnia (2).

To avoid potential effects of aging on plasma cytokine levels (11), patients above the age of 55 yr were excluded from the study. Patients who received treatment with methylphenidate (Ritalin; Ciba Pharmaceutical, Summit, NJ) or sympathomimetic or sympatholytic medications were excluded. All patients were asked to abstain from nonsteroidal antiinflammatory medications for 1 week before the study. Patients with any active infection, including the common cold, or any inflammatory diseases, such as rheumatoid arthritis, were excluded.

Control subjects were recruited from the community. They were in good general health, had no sleep complaints, had normal sleep laboratory findings, and were not taking any medications.

Sleep laboratory procedures

A thorough medical assessment, including physical examination, laboratory tests, and sleep history, was completed for each patient and control subject. All of the patients and control subjects were evaluated in the sleep laboratory for 1 night for 8 h according to standard polysomnographic procedures (12). In addition, narcoleptic and hypersomniac patients were recorded in the sleep laboratory for two daytime naps after nighttime polysomnography (13). The sleep records were scored independently of any knowledge of the experimental conditions according to standardized criteria (12). Throughout the night, respiration was monitored by thermocouples at the nose and mouth (model TCT 1R, Grass Instrument Co., Quincey, MA) and thoracic strain gauges. All-night recordings of hemoglobin oxygen saturation (S_aO₂) were obtained using a cardiorespiratory oximeter (model 8800, Nonin Medical Inc., Plymouth, MN) attached to the finger. The respiratory data were quantified as previously described (10).

Cytokine assays

Single blood samples for measurement of plasma TNF, IL-1ß, and IL-6 were drawn between 0600–0700 h after the completion of the nocturnal sleep laboratory recording. Blood samples were placed on ice immediately and were centrifuged no later than 3 h after the blood was drawn. Plasma was stored at -70 C until assay. All samples were processed in the same manner. Plasma TNF, IL-1ß, and IL-6 were measured by ELISA (R&D Systems, Minneapolis, MN). The intra- and interassay coefficients of variation were from 5.6–6.1% and 7.5–10.4%, respectively, for TNF; 11.3% and 18% for IL-1ß; and from 3.2–8.5% and 3.5–8.7% for IL-6. The lower detection limits for TNF, IL-1ß, and IL-6 were 0.18, 0.1, and 0.094 pg/mL, respectively.

Statistical analyses

The results of parametric values are expressed as the mean ± SE. For comparisons of parametric values between the control group and disorders of EDS, the Dunnett multiple comparison two-tailed test was employed. For comparisons of nonparametric values, we used Fisher’s exact test. The statistical confidence level selected for all analyses was P < 0.05.

To assess the strength of the association between cytokines and the intensity of EDS, we employed the Pearson product-moment correlation within those subjects with nap recordings. Specifically, we calculated the correlation between cytokine levels and the mean nap sleep latency employed as a measure of the intensity of EDS. We further calculated the correlation between cytokine levels and possible confounding factors, i.e. age, body mass index (BMI), minimum S_aO₂, and nocturnal sleep disturbance (percentage of sleep time).

To assess the relative strength of association of EDS as well as possible confounding factors with cytokines, we employed a stepwise multiple regression in the entire group, including the controls. In this analysis, we used cytokines as the dependent variables and evaluated the order of inclusion in the model of the following independent variables: EDS (a categorical variable, i.e. patients with EDS vs. controls), BMI, minimum S_aO₂, nocturnal sleep disturbance (percentage of sleep time), and age. Finally, to indicate the overall amount of variability accounted for by the multiple regression analysis, we report the final variability (r_xy²).

	Results

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Cytokines and daytime sleepiness

The plasma TNF concentration was significantly elevated in apneics and narcoleptics (P < 0.001 and P = 0.001, respectively) compared to that in normal controls (Table 2 and Fig. 1A). No significant difference was detected among the different groups with regard to plasma IL-1ß levels. Plasma IL-6 was markedly elevated only in sleep apneics compared to controls (P = 0.028; Table 2 and Fig. 1B).

View larger version (25K): [in this window] [in a new window]   Figure 1. Plasma TNF and IL-6 levels in normal subjects and patients with EDS. A: *, P < 0.001 vs. normal. B: *, P = 0.028 vs. normal.

When we evaluated the association between the cytokine concentration and the intensity of sleepiness using a continuous measure of EDS (mean sleep latency during naps), plasma IL-6 concentrations correlated positively with intensity of sleepiness in the group of narcoleptics (r_xy = -0.70; P = 0.017) and tended to do so in the combined group of narcoleptics and hypersomniacs (r_xy = -0.42; P = 0.079). Plasma TNF was not correlated with this index of daytime sleepiness.

Cytokines and factors affecting daytime sleepiness

TNF values were positively correlated with the degree of nocturnal sleep disturbance (percent sleep time; r_xy = -0.50; P = 0.001) and the degree of hypoxia (minimum S_aO₂; r_xy = -0.46; P = 0.002), but not with BMI or age.

IL-6 values were positively correlated with BMI (r_xy = 0.63; P < 0.001; Fig. 2), degree of hypoxia (minimum S_aO₂; r_xy = -0.48; P = 0.001), and degree of nocturnal sleep disturbance (percentage of sleep time; r_xy = -0.40; P = 0.006), but not with age, in the entire group of controls and patients.

View larger version (11K): [in this window] [in a new window]   Figure 2. BMI and IL-6 plasma levels are positively correlated.

	Discussion

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Plasma levels of TNF and/or IL-6 were elevated in patients with disorders associated with excessive daytime sleepiness. These elevations were significant in sleep apnea (TNF and IL-6) and narcolepsy (TNF), but not in idiopathic hypersomnia. The lack of significance in the latter group may be due to the small sample size of this cohort and/or to the lesser degree of daytime sleepiness in these patients than in the other patient groups. There was no association between IL-1ß and disorders of EDS, which may be attributed to insufficient sensitivity of the currently available IL-1ß assay to allow measurements within the normal range.

Plasma inflammatory cytokines follow a circadian rhythm, with peaks between 0100–0200 h, when slow wave sleep usually occurs, suggesting a potential physiological role of these cytokines in normal sleep (14, 15, 16). In our EDS patients, we observed elevations during the morning (0600–0700 h), also suggesting a pathophysiological role for these cytokines. The 2- to 3-fold increases in inflammatory cytokines in the plasma of patients with EDS may, in fact, reflect much higher elevations in the production and/or target sites of these cytokines, in this case, we presume, the central nervous system. The underlying mechanisms of the plasma TNF and/or IL-6 elevations in EDS disorders are not clear. The strong positive correlation between IL-6 and BMI is interesting. Also, IL-6 and TNF were highest in the sleep apnea group, which had the highest BMI among the patient groups studied. Plasma TNF concentrations are significantly elevated in obese animals, and its levels best correlate with massive obesity and insulin resistance (17). Our results confirmed this in humans and, in addition, indicated that IL-6 secretion is increased in obese men and women. Interestingly, obesity, even in the absence of sleep apnea, is more frequently associated with subjective complaints of fatigue, EDS, and nocturnal sleep disturbance (10) as well as with higher degrees of objective EDS than those in age- and sex-matched controls (Vgontzas, A., manuscript in preparation). Our results suggest that inflammatory cytokines, particularly IL-6, may be associated with the increased fatigue and sleepiness exhibited by obese subjects.

Recently, in animal and human studies, IL-6 secretion was found to be regulated positively by catecholamines through ß-adrenergic receptors (18, 19). The known increased peripheral sympathetic activity in sleep apnea (20) and obesity (21) could explain the high levels of IL-6 observed in our patients. Furthermore, our data provide evidence that sleep deprivation and, to a lesser extent, hypoxia might play a role in inflammatory cytokine elevation, particularly of TNF, in disorders of EDS and are consistent with previous findings that sleep deprivation in humans leads to elevations in TNF (22).

In conclusion, our study suggests that TNF and IL-6 may play a significant role in mediating sleepiness and fatigue in disorders of EDS in humans. Also, our data point to several potential underlying factors affecting cytokine levels, with obesity playing the strongest role in IL-6 elevation, and sleep disturbance being the strongest factor in TNF elevation.

Received November 13, 1996.

Revised February 5, 1997.

Accepted February 10, 1997.

	References

Top Abstract Introduction Subjects and Methods Results Discussion References

 

1. Bixler EO, Kales A, Soldatos CR, Kales JD, Healey S. 1979 Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry. 11:1257–1269.
2. American Sleep Disorders Association Diagnostic Classification Steering Committee. 1990 International classification of sleep disorders. Diagnostic and coding manual. Rochester: American Sleep Disorders Association.
3. Opp MR, Kapas L, Toth LA. 1992 Cytokine involvement in the regulation of sleep. Proc Soc Exp Biol Med. 201:16–27.[Medline]
4. Moldofsky H, Lue FA, Eisen J, Keystone E, Gorczynski RM. 1986 The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med. 48:309–318.[Abstract/Free Full Text]
5. Kapas L, Hong L, Cady AB, et al. 1992 Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor- and TFN- fragments. Am J Physiol. 263:708–715.
6. Opp M, Obal Jr F, Cady AB, Johannsen L, Krueger JM. 1989 Interleukin-6 is pyrogenic but not somnogenic. Physiol Behav. 45:1069–1972.[CrossRef][Medline]
7. Reincke M, Heppner C, Petzke F, et al. 1994 Impairment of adrenocortical function associated with increased plasma tumor necrosis factor-alpha and interleukin-6 concentrations in African trypanosomiasis. Neuro Immuno Modulation. 1:14–22.
8. Mastorakos G, Chrousos GP, Weber JS. 1993 Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 77:1690–1694.[Abstract]
9. Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP. 1996 Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab. 81:2303–2306.[Abstract]
10. Vgontzas AN, Tan TL, Bixler EO, Martin LF, Shubert D, Kales A. 1994 Sleep apnea and sleep disruption in obese patients. Arch Intern Med. 154:1705–1711.[Abstract]
11. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li G, Ryu S. 1993 Altered regulation of IL-6 production with normal aging: possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol. 150:5219–5230.[Abstract]
12. Rechtschaffen A, Kales A. 1986 A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. NIMH Publication 204. Washington DC: US Government Printing Office.
13. Kales A, Bixler EO, Soldatos CR, Cadieux RJ, Manfredi R, Vela-Bueno A. 1987 Narcolpesy/cataplexy. IV. Diagnostic value of daytime nap recordings. Acta Neurol Scand. 75:223–230.[Medline]
14. Bauer J, Hohagen T, Ebert J, et al. 1994 Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clin Invest. 72:315.[Medline]
15. Sothern RB, Roitman-Johnson B, Kanabrock EL, et al. 1995 Circadian characteristics of interleukin-6 in blood and urine of clinically healthy men. In Vivo. 9:331–340.[Medline]
16. Gudewill S, Pollmacher T, Vedder H, Schreiber W, Fassbender K, Holsboer F. 1992 Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci. 242:53–56.[CrossRef][Medline]
17. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993 Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science 259:87–91.
18. Papanicolaou DA, Petrides JS, Tsigos C, et al. 1996 Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlations with catecholamines. Am J Physiol. 34:E601–E605.
19. DeRijk RH, Boelen A, Tilders FJH, Berkenbosch F. 1994 Induction of plasma interleukin-6 by circulating adrenaline in the rat. Psychoneuroendocrinology. 19:155–163.[CrossRef][Medline]
20. Fletcher EC, Miller J, Schaaf JW, Fletcher JG. 1987 Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep. 10:35–44.[Medline]
21. Reaven GM, Lithel H, Landsberg L. 1996 Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 334:374–381.[Free Full Text]
22. Yamasu K, Shimada Y, Sakaizumi M, Soma GI, Mizuno DI. Activation of the systemic production of tumor necrosis factor after exposure to acute physical stress [Abstract]. Proc of the 3rd Int Conf on Tumor Necrosis Factor and Related Cytokines. 1990; 174.

This article has been cited by other articles:

				M. T. Canales, L.-Y. Lui, B. C. Taylor, A. Ishani, R. Mehra, K. L. Stone, S. Redline, K. E. Ensrud, and for the Osteoporotic Fractures in Men (MrOS) Study Renal function and sleep-disordered breathing in older men Nephrol. Dial. Transplant., July 20, 2008; (2008) gfn364v1. [Abstract] [Full Text] [PDF]

				J L Newton, D E J Jones, E Henderson, L Kane, K Wilton, A D Burt, and C P Day Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance Gut, June 1, 2008; 57(6): 807 - 813. [Abstract] [Full Text] [PDF]

				U. M. Nater, L. S. Youngblood, J. F. Jones, E. R. Unger, A. H. Miller, W. C. Reeves, and C. Heim Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome Psychosom Med, April 1, 2008; 70(3): 298 - 305. [Abstract] [Full Text] [PDF]

				A. J. Sorscher How is Your Sleep: A Neglected Topic for Health Care Screening J Am Board Fam Med, March 1, 2008; 21(2): 141 - 148. [Abstract] [Full Text] [PDF]

				I. A. Nakchbandi, R. Lang, B. Kinder, and K. L. Insogna The Role of the Receptor Activator of Nuclear Factor-{kappa}B Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 967 - 973. [Abstract] [Full Text] [PDF]

				B. Buyse and the participants of working group 2 Treatment effects of sleep apnoea: where are we now? Eur. Respir. Rev., December 1, 2007; 16(106): 146 - 168. [Abstract] [Full Text] [PDF]

				I. A. Harsch Metabolic disturbances in patients with obstructive sleep apnoea syndrome Eur. Respir. Rev., December 1, 2007; 16(106): 196 - 202. [Abstract] [Full Text] [PDF]

				M. L. Okun, M. Hall, and M. E. Coussons-Read Sleep Disturbances Increase Interleukin-6 Production During Pregnancy: Implications for Pregnancy Complications Reproductive Sciences, September 1, 2007; 14(6): 560 - 567. [Abstract] [PDF]

				G. Cavadini, S. Petrzilka, P. Kohler, C. Jud, I. Tobler, T. Birchler, and A. Fontana From the Cover: TNF-{alpha} suppresses the expression of clock genes by interfering with E-box-mediated transcription PNAS, July 31, 2007; 104(31): 12843 - 12848. [Abstract] [Full Text] [PDF]

				E. R. Chasens Obstructive Sleep Apnea, Daytime Sleepiness, and Type 2 Diabetes The Diabetes Educator, May 1, 2007; 33(3): 475 - 482. [Abstract] [Full Text] [PDF]

				C. J. Williams, F. B. Hu, S. R. Patel, and C. S. Mantzoros Sleep Duration and Snoring in Relation to Biomarkers of Cardiovascular Disease Risk Among Women With Type 2 Diabetes Diabetes Care, May 1, 2007; 30(5): 1233 - 1240. [Abstract] [Full Text] [PDF]

				R. Wu, S. Fujii, N.K. Ryan, K.H. Van der Hoek, M.J. Jasper, I. Sini, S.A. Robertson, R.L. Robker, and R.J. Norman Ovarian leukocyte distribution and cytokine/chemokine mRNA expression in follicular fluid cells in women with polycystic ovary syndrome Hum. Reprod., February 1, 2007; 22(2): 527 - 535. [Abstract] [Full Text] [PDF]

				N. Chouri-Pontarollo, J.-C. Borel, R. Tamisier, B. Wuyam, P. Levy, and J.-L. Pepin Impaired Objective Daytime Vigilance in Obesity-Hypoventilation Syndrome: Impact of Noninvasive Ventilation Chest, January 1, 2007; 131(1): 148 - 155. [Abstract] [Full Text] [PDF]

				A. N. Vgontzas, S. Pejovic, E. Zoumakis, H. M. Lin, E. O. Bixler, M. Basta, J. Fang, A. Sarrigiannidis, and G. P. Chrousos Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E253 - E261. [Abstract] [Full Text] [PDF]

				R. Wolk and V. K. Somers Sleep Apnoea & Hypertension: Physiological bases for a causal relation: Sleep and the metabolic syndrome Exp Physiol, January 1, 2007; 92(1): 67 - 78. [Abstract] [Full Text] [PDF]

				A. N VGONTZAS, E. O BIXLER, and G. P CHROUSOS Obesity-Related Sleepiness and Fatigue: The Role of the Stress System and Cytokines Ann. N.Y. Acad. Sci., November 1, 2006; 1083(1): 329 - 344. [Abstract] [Full Text] [PDF]

				S. Ryan, C. T. Taylor, and W. T. McNicholas Predictors of Elevated Nuclear Factor-{kappa}B-dependent Genes in Obstructive Sleep Apnea Syndrome Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 824 - 830. [Abstract] [Full Text] [PDF]

				R. Mehra, A. Storfer-Isser, H. L. Kirchner, N. Johnson, N. Jenny, R. P. Tracy, and S. Redline Soluble interleukin 6 receptor: a novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med, September 18, 2006; 166(16): 1725 - 1731. [Abstract] [Full Text] [PDF]

				H. Himmerich, P. A. Beitinger, S. Fulda, R. Wehrle, J. Linseisen, G. Wolfram, S. Himmerich, K. Gedrich, T. C. Wetter, and T. Pollmacher Plasma Levels of Tumor Necrosis Factor {alpha} and Soluble Tumor Necrosis Factor Receptors in Patients With Narcolepsy. Arch Intern Med, September 18, 2006; 166(16): 1739 - 1743. [Abstract] [Full Text] [PDF]

				R. von Kanel, J. E. Dimsdale, P. J. Mills, S. Ancoli-Israel, T. L. Patterson, B. T. Mausbach, and I. Grant Effect of Alzheimer caregiving stress and age on frailty markers interleukin-6, C-reactive protein, and d-dimer. J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2006; 61(9): 963 - 969. [Abstract] [Full Text] [PDF]

				K. Kobayashi, Y. Nishimura, T. Shimada, S. Yoshimura, Y. Funada, M. Satouchi, and M. Yokoyama Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome Chest, March 1, 2006; 129(3): 632 - 637. [Abstract] [Full Text] [PDF]

				A. S Greenberg and M. S Obin Obesity and the role of adipose tissue in inflammation and metabolism Am. J. Clinical Nutrition, February 1, 2006; 83(2): 461S - 465S. [Abstract] [Full Text] [PDF]

				C. A. Everson Clinical assessment of blood leukocytes, serum cytokines, and serum immunoglobulins as responses to sleep deprivation in laboratory rats Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R1054 - R1063. [Abstract] [Full Text] [PDF]

				B. Chen, S. Tsui, and T. J. Smith IL-1{beta} Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy J. Immunol., July 15, 2005; 175(2): 1310 - 1319. [Abstract] [Full Text] [PDF]

				R. Schulz The vascular micromilieu in obstructive sleep apnoea Eur. Respir. J., May 1, 2005; 25(5): 780 - 782. [Full Text] [PDF]

				W. Lim, S. Hong, R. Nelesen, and J. E. Dimsdale The Association of Obesity, Cytokine Levels, and Depressive Symptoms With Diverse Measures of Fatigue in Healthy Subjects Arch Intern Med, April 25, 2005; 165(8): 910 - 915. [Abstract] [Full Text] [PDF]

				R. D. Vorona, M. P. Winn, T. W. Babineau, B. P. Eng, H. R. Feldman, and J. C. Ware Overweight and Obese Patients in a Primary Care Population Report Less Sleep Than Patients With a Normal Body Mass Index Arch Intern Med, January 10, 2005; 165(1): 25 - 30. [Abstract] [Full Text] [PDF]

				T. Tazaki, K. Minoguchi, T. Yokoe, K. T. R. Samson, H. Minoguchi, A. Tanaka, Y. Watanabe, and M. Adachi Increased Levels and Activity of Matrix Metalloproteinase-9 in Obstructive Sleep Apnea Syndrome Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1354 - 1359. [Abstract] [Full Text] [PDF]

				J. A. McKenzie, E. P. Weiss, I. A. Ghiu, O. Kulaputana, D. A. Phares, R. E. Ferrell, and J. M. Hagberg Influence of the interleukin-6 -174 G/C gene polymorphism on exercise training-induced changes in glucose tolerance indexes J Appl Physiol, October 1, 2004; 97(4): 1338 - 1342. [Abstract] [Full Text] [PDF]

				A. N. Vgontzas, E. Zoumakis, H.-M. Lin, E. O. Bixler, G. Trakada, and G. P. Chrousos Marked Decrease in Sleepiness in Patients with Sleep Apnea by Etanercept, a Tumor Necrosis Factor-{alpha} Antagonist J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4409 - 4413. [Abstract] [Full Text] [PDF]

				U. Hatipoglu and I. Rubinstein Inflammation and Obstructive Sleep Apnea Syndrome: How Many Ways Do I Look at Thee? Chest, July 1, 2004; 126(1): 1 - 2. [Full Text] [PDF]

				T. Skurk, V. van Harmelen, and H. Hauner Angiotensin II Stimulates the Release of Interleukin-6 and Interleukin-8 From Cultured Human Adipocytes by Activation of NF-{kappa}B Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1199 - 1203. [Abstract] [Full Text] [PDF]

				J. Faldt, I. Wernstedt, S. M. Fitzgerald, K. Wallenius, G. Bergstrom, and J.-O. Jansson Reduced Exercise Endurance in Interleukin-6-Deficient Mice Endocrinology, June 1, 2004; 145(6): 2680 - 2686. [Abstract] [Full Text] [PDF]

				R. Tauman, A. Ivanenko, L. M. O'Brien, and D. Gozal Plasma C-Reactive Protein Levels Among Children With Sleep-Disordered Breathing Pediatrics, June 1, 2004; 113(6): e564 - e569. [Abstract] [Full Text]

				H. K. Meier-Ewert, P. M. Ridker, N. Rifai, M. M. Regan, N. J. Price, D. F. Dinges, and J. M. Mullington Effect of sleep loss on C-Reactive protein, an inflammatory marker of cardiovascular risk J. Am. Coll. Cardiol., February 18, 2004; 43(4): 678 - 683. [Abstract] [Full Text] [PDF]

				A. S. M. Shamsuzzaman, B. J. Gersh, and V. K. Somers Obstructive Sleep Apnea: Implications for Cardiac and Vascular Disease JAMA, October 8, 2003; 290(14): 1906 - 1914. [Abstract] [Full Text] [PDF]

				K. Stenlof, I. Wernstedt, T. Fjallman, V. Wallenius, K. Wallenius, and J.-O. Jansson Interleukin-6 Levels in the Central Nervous System Are Negatively Correlated with Fat Mass in Overweight/Obese Subjects J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4379 - 4383. [Abstract] [Full Text] [PDF]

				J. K. Kiecolt-Glaser, K. J. Preacher, R. C. MacCallum, C. Atkinson, W. B. Malarkey, and R. Glaser Chronic stress and age-related increases in the proinflammatory cytokine IL-6 PNAS, July 22, 2003; 100(15): 9090 - 9095. [Abstract] [Full Text] [PDF]

				L. Dyugovskaya, P. Lavie, and L. Lavie Phenotypic and Functional Characterization of Blood {gamma}{delta} T Cells in Sleep Apnea Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 242 - 249. [Abstract] [Full Text] [PDF]

<